# Coronary Disease Seen in Diabetes Before Age 40

BY MITCHEL L. ZOLER

ATLANTA — Two-thirds of young adults with diabetes who were aged 40 years or younger had significant coronary artery atherosclerosis, on the basis of coronary CT examinations of 130 such patients at one U.S. medical center.

When compared with more than 3,500 similarly aged young adults without diabetes, patients with diabetes also had an

adjusted, fourfold increased prevalence of coronary atherosclerosis, Dr. Nikhil Daga and his associates reported in a poster at the annual meeting of the American College of Cardiology.

These findings run counter to current recommendations of the American Diabetes Association, which recommend routinely starting statin treatment of patients with diabetes only in those older than 40 years (Diabetes Care 2010;33:S11-61).

"ADA guidelines should consider statin use in patients aged 40 or younger who exhibit subclinical atherosclerosis to reduce future cardiovascular disease events in this vulnerable population," noted Dr. Daga of Harbor-UCLA Medical Center in Torrance, Calif., and his associates.

The researchers performed coronary CT examinations on 3,711 people aged up to age 40 years, including 130 patients with diabetes and 3,581 people without diabetes. The average age of the entire group was 36 years, and 54% were men.

The study presumed that the presence of any coronary calcium indicated significant atherosclerosis.

The CT examinations revealed a low coronary calcium score of 1-99 in 52% of the patients with diabetes and in 24% of those without diabetes. An intermediate score of 100-399 occurred in 12% of those with diabetes and in 2% of people without diabetes. A high score of 400 or greater occurred in 4% of those with diabetes and in 0.5% of those without diabetes. Overall, 68% of the patients with diabetes had some degree of coronary artery calcification, compared with a 27% prevalence in people without diabetes.

Dr. Daga said that he had no disclosures. Among his associates, the only disclosure was from Dr. Matthew Budoff, who is on the speakers bureau for General Electric, a company that markets CT equipment.

## Bystolic ()

(nehivolol) tablets 2.5 mg, 5 mg, 10 mg and 20 mg Rx Only

### INDICATIONS AND USAGE

BYSTOLIC is indicated for the treatment of hypertension. BYSTOLIC may be used alone or in combination with other antihypertensive agents.

### CONTRAINDICATIONS

CONTRAINDICATIONS

SYSTOLIC is contraindicated in patients with severe bradycardia, heart block greater than first degree, cardiogenic shock, decompensated cardiac failure, sick sinus syndrome (unless a permanent pacemaker is in place), or severe hepatic impairment (Child-Pugh >B), and in patients who are hypersensitive to any component of this product.

### Abrupt Cessation of Therapy

Abrupt Cessation of Therapy Patients with coronary artery disease treated with BYSTOLIC should be advised against abrupt discontinuation of therapy. Severe exacerbation of angina and the occurrence of myocardial infarction and ventricular arrhythmias have been reported in patients with coronary artery disease following the abrupt discontinuation of therapy with  $\beta$ -blockers. Myocardial infarction and ventricular arrhythmias may occur with or without preceding exacerbation of the angina pectoris. Even patients withou with of without preceding exacerbation of the ariginal pectors. Event patients without overt coronary artery disease should be cautioned against interruption or abrupt discontinuation of therapy. As with other  $\beta$ -blockers, when discontinuation of BYSTOLIC is planned, patients should be carefully observed and advised to minimize physical activity. BYSTOLIC should be tapered over 1 to 2 weeks when possible. If the angina worsens or acute coronary insufficiency develops, it is recommended that BYSTOLIC be promptly reinstituted, at least temporarily.

that MYSTOLIC be promipuly remistrated, at reask emporating.

Cardiac Failure

Sympathetic stimulation is a vital component supporting circulatory function in the setting of congestive heart failure, and β-blockade may result in further depression of myocardial contractility and precipitate more severe failure. In patients who have compensated congestive heart failure, BYSTOLIC should be administered cautiously. If heart failure worsens, discontinuation of BYSTOLIC should be considered.

### Angina and Acute Myocardial Infarction BYSTOLIC was not studied in patients with angina pectoris or who had a recent MI.

Bronchospastic Diseases In general, patients with bronchospastic diseases should not receive  $\beta$ -blockers.

In general, patients with pronchospastic diseases should not receive β-blockers.

Anesthesia and Major Surgery

If BYSTOLIC is to be continued perioperatively, patients should be closely monitored when anesthetic agents which depress myocardial function, such as ether, cyclopropane, and trichloroethylene, are used. If β-blocking therapy is withdrawn prior to major surgery, the impaired ability of the heart to respond to reflex adrenergic stimuli may augment the risks of general anesthesia and surgical procedures.

procedures. The  $\beta$ -blocking effects of BYSTOLIC can be reversed by  $\beta$ -agonists, e.g., dobutamine or isoproterenol. However, such patients may be subject to protracted severe hypotension. Additionally, difficulty in restarting and maintaining the heartbeat has been reported with  $\beta$ -blockers.

### Diabetes and Hypoglycemia

Diabetes and Hypoglycemia P-blockers may mask some of the manifestations of hypoglycemia, particularly tachycardia. Nonselective P-blockers may potentiate insulin-induced hypoglycemia and delay recovery of serum glucose levels. It is not known whether nebivolol has these effects. Patients subject to spontaneous hypoglycemia, or diabetic patients receiving insulin or oral hypoglycemic agents, should be advised about these possibilities and nebivolol should be used with caution.

Thyrotoxicosis
β-blockers may mask clinical signs of hyperthyroidism, such as tachycardia. Abrupt withdrawal of β-blockers may be followed by an exacerbation of the symptoms of hyperthyroidism or may precipitate a thyroid storm.

### Peripheral Vascular Disease

B-blockers can precipitate or aggravate symptoms of arterial insufficiency in patients with peripheral vascular disease. Caution should be exercised in these patients.

with peripheral vascular disease. Laution should be exercised in these patients.

Mon-dihydropyridine Calcium Channel Blockers

Because of significant negative inotropic and chronotropic effects in patients treated with β-blockers and calcium channel blockers of the verapamil and dilliazem type, caution should be used in patients treated concomitantly with these agents and ECG and blood pressure should be monitored.

PRECAUTIONS
Use with CYP2D6 Inhibitors
Nebivolol exposure increases with inhibition of CYP2D6 (see Drug Interactions).
The dose of BYSTOLIC may need to be reduced.

Impaired Renal Function
BYSTOLIC should be used with caution in patients with severe renal impairment
because of decreased renal clearance. BYSTOLIC has not been studied in patients
receiving dialysis.

Impaired Hepatic Function
BYSTOLIC should be used with caution in patients with moderate hepatic impairment because of decreased metabolism. Since BYSTOLIC has not been studied in patients with severe hepatic impairment, BYSTOLIC is contraindicated in this population (see CLINICAL PHARMACOLOGY, Special Populations and DOSAGE AND ADMINISTRATION).

### Risk of Anaphylactic Reactions

While taking β-blockers, patients with a history of severe anaphylactic reactions to while damily p-indices, patients with a history of severe anaphytactic reactions to a variety of allergens may be more reactive to repeated challenge either accidental, diagnostic, or therapeutic. Such patients may be unresponsive to the usual doses of epinephrine used to treat allergic reactions. In patients with known or suspected pheochromocytoma, an  $\alpha$ -blocker should be initiated prior to the use of any  $\beta$ -blocker.

### Information for Patients

Intormation for Patients
Patients should be advised to take BYSTOLIC regularly and continuously, as directed. PYSTOLIC can be taken with or without food. If a dose is missed, the patient should take the next scheduled dose only (without doubling it). Patients should not interrupt or discontinue BYSTOLIC without consulting the physician.

Patients should know how they react to this medicine before they operate automobiles, use machinery, or engage in other tasks requiring alertness.

Patients should be advised to consult a physician if any difficulty in breathing occurs, or if they develop signs or symptoms of worsening congestive heart failure such as weight gain or increasing shortness of breath, or excessive bradycardia.

Patients subject to spontaneous hypoglycemia, or diabetic patients receiving insulin or oral hypoglycemic agents, should be cautioned that β-blockers may mask some of the manifestations of hypoglycemia, particularly tachycardia. Nebivolol should be used with caution in these patients.

### **Drug Interactions**

Drug Interactions

PVSTOLIC should be used with care when myocardial depressants or inhibitors of AV conduction, such as certain calcium antagonists (particularly of the phenylalkylamine (verapamil) and benzothiazepine [dilitazem) classes), or antiarrhythmic agents, such as disopyramide, are used concurrently. Both digitalis glycosides and β-blockers slow atrioventricular conduction and decrease heart rate. Concomitant use can increase the risk of bradycardia.

use can increase the risk of bradycardia.

BYSTOLIC should not be combined with other β-blockers. Patients receiving catecholamine-depleting drugs, such as reserpine or guanethidine, should be closely monitored, because the added β-blocking action of BYSTOLIC may produce excessive reduction of sympathetic activity. In patients who are receiving BYSTOLIC and clonidine, BYSTOLIC should be discontinued for several days before the gradual tapering of clonidine.

EYP206 Inhibitors: Use caution when BYSTOLIC is co-administered with CYP206 inhibitors (quindine, propatenone, fluoxetine, paroxetine, etc.) (see CLINICAL PHARMACOLOGY, Drug Interactions).

Carcinogenesis, Mulagenesis, Impairment of Fertility
In a two-year study of nebivolol in mice, a statistically significant increase it the incidence of testicular Leydig cell hyperplasia and adenomas was observed in 40 mg/kg/day (5 times the maximally recommended human dose of 40 mg on mg/m² basis). Similar findings were not reported in mice administered doses equi mg/m² basis). Similar findings were not reported in mice administered doses equal to approximately 0.3 or 1.2 times the maximum recommended human dose. No evidence of a tumorigenic effect was observed in a 24-month study in Wistar rats receiving doses of nebivolol 2.5, 10 and 40 mg/kg/day (equivalent to 0.6, 2.4, and 10 times the maximally recommended human dose). Co-administration of dihydrotestosterone reduced blood LH levels and prevented the Leydig cell hyperplasia, consistent with an indirect LH-mediated effect of nebivolol in mice and not thought to be clinically relevant in man.

thought to be clinically relevant in man. A randomized, double-blind, placebo- and active-controlled, parallel-group study in healthy male volunteers was conducted to determine the effects of nebivolol on adrenal function, luteinizing hormone, and testosterone levels. This study demonstrated that 6 weeks of daily dosing with 10 mg of nebivolol had no significant effect on ACTH-stimulated mean serum cortisol AUC<sub>0-120 min</sub>, serum LH, or serum total testosterone.

or serum total testosterone. Effects on spermatogenesis were seen in male rats and mice at ≥40 mg/kg/day (10 and 5 times the MRHD, respectively). For rats the effects on spermatogenesis were not reversed and may have worsened during a four-week recovery period. The effects of nebivolo on sperm in mice, however, were partially reversible. Mutagenesis: Nebivolo was not genotoxic when tested in a battery of assays (Ames, *in vitro* mouse lymphoma TK-i<sup>+</sup>, *in vitro* human peripheral lymphocyte chromosome aberration, *in vivo* Drosophila melanogaster sex-linked recessive lethal, and *in vivo* mouse bone marrow micronucleus tests).

### Pregnancy: Teratogenic Effects. Pregnancy Category C: Decreased pup body weights occurred at 1.25 and 2.5 mg/kg in rats, when exposed

during the perinatal period (late gestation, parturition and lactation). At 5 mg/kg and higher doses (1.2 times the MRHD), prolonged gestation, dystocia and reduced emal care were produced with corresponding increases in late fetal deaths and iriths and decreased birth weight, live litter size and pup survival. Insufficient bers of pups survived at 5 mg/kg to evaluate the offspring for reproductive correspondence.

performance.

In studies in which pregnant rats were given nebivolol during organogenesis, reduced fetal body weights were observed at maternally toxic doses of 20 and 40 mg/kg/day (5 and 10 times the MRHD), and small reversible delays in sternal and thoracic ossification associated with the reduced fetal body weights and a small increase in resorption occurred at 40 mg/kg/day (10 times the MRHD). No adverse effects on embryo-fetal viability, sex, weight or morphology were observed in studies in which nebivolol was given to pregnant rabbits at doses as high as 20 mg/kg/day (10 times the MRHD).

20 mlykgday (10 mines are wikhol).

Labor and Delivery

Nebivolol caused prolonged gestation and dystocia at doses ≥5 mg/kg in rats (1.2 times the MRHD). These effects were associated with increased fetal deaths and stillborn pups, and decreased birth weight, live litter size and pup survival rate, events that occurred only when nebivolol was given during the perinatal period (late gestation, parturition and lactation).

No studies of nebivolol were conducted in pregnant women. BYSTOLIC should be used during pregnancy only if the potential benefit justifies the potential risk

### Nursing Mothers

Studies in rats have shown that nebivolol or its metabolites cross the placental barrier and are excreted in breast milk. It is not known whether this drug is excreted

Because of the potential for  $\beta$ -blockers to produce serious adverse reactions in nursing infants, especially bradycardia, BYSTOLIC is not recommended during pureling.

Geriatric Use
Of the 2800 patients in the U.S.-sponsored placebo-controlled clinical hypertension studies, 478 patients were 65 years of age or older. No overall differences in efficacy or in the incidence of adverse events were observed between older and younger natients.

Pediatric Use
Safety and effectiveness in pediatric patients have not been established. Pediatric studies in ages newborn to 18 years old have not been conducted because of incomplete characterization of developmental toxicity and possible adverse effects on long-term fertility (see Carcinogenesis, Mutagenesis, and Impairment of

ADVERSE REACTIONS

The data described below reflect worldwide clinical trial exposure to BYSTOLIC in 6545 patients, including 5038 patients treated for hypertension and the remaining 1507 subjects treated for other cardiovascular diseases. Doses ranged from 0.5 mg to 40 mg. Patients received BYSTOLIC for up to 24 months, with over 1900 patients reated for at least 6 months, and approximately 1300 patients for more than one year. In placebo-controlled clinical trials comparing BYSTOLIC with placebo, discontinuation of therapy due to adverse events was reported in 2.8% of patients treated with nebivolol and 2.2% of patients ginen placebo. The most common adverse events that led to discontinuation of BYSTOLIC were headache (0.4%), nausea (0.2%) and bradycardia (0.2%).

nausea (0.2%) and bradycardia (0.2%).

Adverse Reactions in Controlled Trials

Table 1 lists treatment-emergent signs and symptoms that were reported in three 12week, placebo-controlled monotherapy trials involving 1597 hypertensive patients 
treated with either 5 mg, 10 mg or 20-40 mg of BYSTOLIC and 205 patients given 
placebo and for which the rate of occurrence was at least 1% of patients treated with 
nebivolol and greater than the rate for those treated with placebo in at least one dose

Table 1. Treatment-Emergent Adverse Events with an Incidence (over 6 weeks)  $\geq \! 1\%$  in BYSTOLIC-Treated Patients and at a Higher Frequency than Placebo-Treated Patients

	Placebo	Nebivolol 5 mg	Nebivolol 10 mg	Nebivolol 20-40 mg
	(n = 205) (%)	(n = 459) (%)	(n = 461) (%)	(n = 677) (%)
Headache	6	9	6	7
Fatigue	1	2	2	5
Dizziness	2	2	3	4
Diarrhea	2	2	2	3
Nausea	0	1	3	2
Insomnia	0	1	1	1
Chest pain	0	0	1	1
Bradycardia	0	0	0	1
Dyspnea	0	0	1	1
Rash	0	0	1	1
Peripheral edema	0	1	1	1

Other Adverse Events Observed During Worldwide Clinical Trials
Listed below are other reported adverse events with an incidence of at least 1% in the more than 5300 patients treated with BYSTOLIC in controlled or open-label trials, whether or not attributed to treatment, except for those already appearing in Table 1, terms too general to be informative, minor symptoms, or events unlikely to be attributable to drug because they are common in the population. These adverse events were in most cases observed at a similar frequency in placebo-treated patients in the controlled studies.

### Body as a Whole: asthenia.

Gastrointestinal System Disorders: abdominal pain

Metabolic and Nutritional Disorders: hypercholesterolemia and hyperuricemia Nervous System Disorders: paraesthesia

Laboratory
In controlled monotherapy trials, BYSTOLIC was associated with an increase in BUN, uric acid, triglycerides and a decrease in HDL cholesterol and platelet count.

BUN, uric acid, triglycerides and a decrease in HDL cholesterol and platelet count.

Events Identified from Spontaneous Reports of BYSTOLIC Received Worldwide
The following adverse events have been identified from spontaneous reports of
BYSTOLIC received worldwide and have not been listed elsewhere. These adverse
events have been chosen for inclusion due to a combination of seriousness,
frequency of reporting or potential causal connection to BYSTOLIC. Events common
in the population have generally been omitted. Because these events were reported
voluntarily from a population of uncertain size, it is not possible to estimate their
frequency or establish a causal relationship to BYSTOLIC exposure: abnormal
hepatic function (including increased AST, ALT and bilirubin), acute pulmonary
edema, acute renal failure, atrioventricular block (both second- and third-degree),
bronchospasm, erectile dystruction, hypersensitivity (including urticaria, allergic
vasculitis and rare reports of angioedema), myocardial infarction, purittus,
sporiasis, Raynaud's phenomenon, peripheral ischemia/claudication, somnolence,
syncope, thrombocytopenia, various rashes and skin disorders, vertigo, and
vomiting.

### OVERDOSAGE

In clinical trials and worldwide postmarketing experience there were reports of BYSTOLIC overdose. The most common signs and symptoms associated with BYSTOLIC overdosage are bradycardia and hypotension. Other important adverse events reported with BYSTOLIC overdose include cardiac failure, dizziness, hypoglycemia, fatigue and vomiting. Other adverse events associated with B-blocker overdose include bronchospasm and heart block.

The largest known ingestion of BYSTOLIC worldwide involved a patient who ingested up to 500 mg of BYSTOLIC along with several 100 mg tablets of acetyslaticytic acid in a suicide attempt. The patient experienced hyperhidrosis, pallor, depressed level of consciousness, hypokinesia, hypotension, sinus bradycardia, hypoglycemia, hypokalemia, respiratory failure and vomitting. The patient represented n clinical trials and worldwide postmarketing experience there were reports of

Due to extensive drug binding to plasma proteins, hemodialysis is not expected to

enhance nebivolol clearance.

If overdose occurs, BYSTOLIC should be stopped and general supportive and

specific symptomatic treatment should be provided. Based on expected pharma-cologic actions and recommendations for other  $\beta$ -blockers, the following general measures should be considered when clinically warranted: Bradycardia: Administer IV atropine. If the response is inadequate, isoproterenol or another agent with positive chronotropic properties may be given cautiously. Under some circumstances, transthoracic or transvenous pacemaker placement

Hypotension: Administer IV fluids and vasopressors. Intravenous glucagon may be useful.

Heart Block (second or third degree): Patients should be carefully monitored and treated with isoproterenol infusion. Under some circumstances, transthoracic or transvenous pacemaker placement may be necessary.

Congestive Heart Failure: Initiate therapy with digitalis glycoside and diuretics. In certain cases, consideration should be given to the use of inotropic and vasodilating agents. Bronchospasm: Administer bronchodilator therapy such as a short-acting inhaled

β<sub>2</sub>-agonist and/or aminophylline. by agonist and of animophymno.

Hypoglycemia: Administer IV alucose. Repeated doses of IV alucose or possibly

glucagon may be required. glucagion may be required.

In the event of intoxication where there are symptoms of shock, treatment must be continued for a sufficiently long period consistent with the 12-19 hour effective half-life of BYSTOLIC. Supportive measures should continue until clinical stability

Call the National Poison Control Center (800-222-1222) for the most current information on  $\beta\text{-}blocker$  overdose treatment.

Forest Pharmaceuticals, Inc.
Subsidiary of Forest Laboratories, Inc.
St. Louis, M0 63045, USA
Licensed from Mylan Laboratories, Inc.
Under license from Janssen
Pharmaceutica N.V., Beerse, Belgium

© 2008 Forest Laboratories, Inc.

# Valproate Use For Epilepsy May Prevent MI

ATLANTA — Patients with epilepsy who were treated with valproate had a markedly lower risk of acute MI than the general Danish population in a large case-control study.

This is a particularly intriguing observation in light of a recent report that a diagnosis of epilepsy was associated with nearly a fivefold increased risk of MI during longitudinal follow-up after adjustment for age, gender, and education (Brain 2009;132:2798-804).

The implication of the Danish study is that valproate is an especially attractive antiepileptic therapy, particularly in patients with high levels of the standard cardiovascular risk factors, according to Dr. Jonas B. Olesen of Gentofte University Hospital, Copenhagen.

At the annual scientific session of the American College of Cardiology, Dr. Olesen reported on 9,273 patients with epilepsy who started taking valproate during 1997-2006. Each subject was matched by age and gender with 10 controls.

In a Cox proportional-hazards analysis, valproate-treated epileptic patients had a 20% lower relative risk of MI during follow-up than did controls, but a 46% increased risk of all-cause mortality.

However, upon more extensive adjustment for prior stroke or MI, Charlson Comorbidity Index score, concomitant medications, and socioeconomic status, both groups had similar risk of all-cause mortality. Moreover, this adjustment for background comorbidity and other potential confounders also had the effect of magnifying the apparent impact of valproate on MI risk reduction.

Dr. Olesen indicated that he has no relevant financial relationships.

-Bruce Jancin